Pfizer says Ibrance gives some breast cancer patients more time to survive

Shares of Pfizer Inc. PFE,
+ 0.71%
earned 0.2% in presale on Thursday, after the company said peer-reviewed research shows that Ibrance has improved survival among about 1,400 breast cancer patients when used as first-line therapy in combination with the aromatase inhibitor letrozole. Patients taking combination therapy reported 20 months of actual progression-free survival compared with approximately 12 months reported by patients taking letrozole alone. Ibrance, which received regulatory approval in the U.S. as a first-line treatment in 2017, generated revenue of $ 5.4 billion in 2020. Pfizer shares have risen 26.3% over the past 12 months, while the broader S&P 500 SPX ,,
gained 58.9%.